| Market Capitalization (Millions $) |
3,440 |
| Shares
Outstanding (Millions) |
303 |
| Employees |
562 |
| Revenues (TTM) (Millions $) |
79 |
| Net Income (TTM) (Millions $) |
-144 |
| Cash Flow (TTM) (Millions $) |
-83 |
| Capital Exp. (TTM) (Millions $) |
36 |
Business Description
Abcellera Biologics Inc is a biotech company specializing in the development of fully human monoclonal antibodies. The company was founded in 2012 by a team of scientists from the University of British Columbia, and it has since grown to become one of the world's leading developers of innovative antibody-based therapies.
Using its proprietary technology, Abcellera is able to rapidly discover and develop human antibodies against a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. The company's technology is based on a high-throughput screening platform that can analyze millions of immune cells in a matter of days, allowing for the rapid identification of promising candidates.
Abcellera's technology is particularly well-suited to the development of therapies against rapidly evolving viruses, such as COVID-19. In early 2020, Abcellera partnered with pharmaceutical company Eli Lilly to develop a monoclonal antibody treatment for COVID-19. The resulting drug, bamlanivimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020.
In addition to its work on COVID-19, Abcellera is also developing therapies for a range of other diseases, including cancer and autoimmune disorders. The company has partnerships with a number of pharmaceutical companies, including Pfizer, GSK, and Novartis, and it has raised over $500 million in funding to date.
Abcellera's innovative approach to developing antibody-based therapies has earned the company numerous accolades, including being named one of the most innovative companies in biotech by Fast Company. With its cutting-edge technology and strong partnerships with the pharmaceutical industry, Abcellera is well-positioned to continue making breakthroughs in the development of novel therapeutics.
Company Address: 150 W 4th Avenue Vancouver 0 BC
Company Phone Number: 559-9005 Stock Exchange / Ticker: NASDAQ ABCL
|
1.24%